| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
C-Myc Blocking Peptide is synthetically produced from the 400-454 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
MYC |
| Gene ID: |
4609 |
| Uniprot ID: |
MYC_HUMAN |
| Immunogen Region: |
400-454 |
| Immunogen: |
Synthetic peptide taken within amino acid region 400-454 on human cMyc protein. |
| Post Translational Modifications | Phosphorylated by PRKDC. Phosphorylation at Ser-344 by PIM2 leads to the stabilization of MYC. Phosphorylation at Ser-77 by CDK2 prevents Ras-induced senescence. Phosphorylated at Ser-77 by DYRK2.this primes the protein for subsequent phosphorylation by GSK3B at Thr-73. Phosphorylation at Thr-73 and Ser-77 by GSK3 is required for ubiquitination and degradation by the proteasome. Dephosphorylation at Ser-77 by protein phosphatase 2A (PPP2CA) promotes its degradation.interaction with PPP2CA is enhanced by AMBRA1. Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-73 and Ser-77, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28 but by USP36, due to the lack of interaction between isoform 3 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRPC4AP) complex. Ubiquitinated by TRIM6 in a phosphorylation-independent manner. |
| Function | Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CACGATG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells. Functions with TAF6L to activate target gene expression through RNA polymerase II pause release. Positively regulates transcription of HNRNPA1, HNRNPA2 and PTBP1 which in turn regulate splicing of pyruvate kinase PKM by binding repressively to sequences flanking PKM exon 9, inhibiting exon 9 inclusion and resulting in exon 10 inclusion and production of the PKM M2 isoform. |
| Peptide Name | Myc Proto-Oncogene ProteinClass E Basic Helix-Loop-Helix Protein 39Bhlhe39Proto-Oncogene C-MycTranscription Factor P64 |
| Database Links | Reactome: R-HSA-1362277Reactome: R-HSA-201556Reactome: R-HSA-2122947Reactome: R-HSA-2173796Reactome: R-HSA-2644606Reactome: R-HSA-2894862Reactome: R-HSA-4411364Reactome: R-HSA-5687128Reactome: R-HSA-5689880Reactome: R-HSA-6785807Reactome: R-HSA-69202Reactome: R-HSA-69656Reactome: R-HSA-8866911Reactome: R-HSA-8951430Reactome: R-HSA-9018519Reactome: R-HSA-9616222Reactome: R-HSA-9818749 |
| Cellular Localisation | NucleusNucleoplasmNucleolus |
| Alternative Peptide Names | Myc Proto-Oncogene Protein proteinClass E Basic Helix-Loop-Helix Protein 39 proteinBhlhe39 proteinProto-Oncogene C-Myc proteinTranscription Factor P64 proteinMYC proteinBHLHE39 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
